Preliminary studies suggest that Retatrutide – a dual activator of GLP-1 and a related hormone receptors – may provide a considerable breakthrough in metabolic management therapies. Beyond existing therapies, the peptide seems to affect appetite and metabolic expenditure by means of distinct rout